TWYNEO, developed by Sol-Gel, is a novel fixed-dose combination therapy for acne vulgaris. It combines minocycline, one of the most widely prescribed oral antibiotics for acne, with Sol-Gel’s proprietary 5% benzoyl peroxide (BPO) gel. This groundbreaking dual-action formulation effectively targets both the underlying causes of acne and reduces the presence of P. acnes bacteria on the skin’s surface.
Acne affects millions of people worldwide and can have a significant impact on their quality of life. While there are various available treatments, the efficacy and tolerability of many options remain areas of concern. The introduction of TWYNEO offers new hope for patients, providing a convenient once-daily application that addresses both inflammatory and non-inflammatory acne lesions.
Through this asset purchase agreement, Sol-Gel will grant Beimei Pharma exclusive rights to commercialize TWYNEO in China, Hong Kong, Macau, Taiwan, and Israel. Beimei Pharma, a well-established pharmaceutical company with a strong presence in these regions, will leverage its extensive market knowledge and distribution network to ensure TWYNEO reaches healthcare providers and patients efficiently.
This collaboration represents a significant milestone for both Sol-Gel and Beimei Pharma. Sol-Gel aims to expand its global presence by accessing the rapidly growing markets in Mainland China, Hong Kong, Macau, Taiwan, and Israel. With extensive experience in drug development and commercialization, Beimei Pharma is an ideal partner to introduce TWYNEO to these regions, where there is a growing demand for innovative dermatological treatments.
Dr. Alon Seri-Levy, CEO of Sol-Gel, expressed his enthusiasm regarding the collaboration, stating, We are excited to enter into this asset purchase agreement with Beimei Pharma, an established pharmaceutical company with a strong track record. Their commitment to bringing innovative therapies to patients aligns with our mission to address dermatological unmet needs worldwide.
Beimei Pharma’s CEO, Mr. Jing Wu, also expressed his confidence in the partnership, noting, TWYNEO represents a significant advancement in acne treatment, and we are thrilled to bring this innovative solution to healthcare providers and patients in the regions we serve. We believe this collaboration with Sol-Gel will not only benefit patients but also create new opportunities for our business.
The asset purchase agreement between Sol-Gel and Beimei Pharma is a testament to the growing importance of partnerships in advancing dermatological innovation. By combining Sol-Gel’s expertise in developing breakthrough formulations with Beimei Pharma’s strong marketing and distribution capabilities, TWYNEO is expected to make a profound impact on the lives of acne sufferers in Mainland China, Hong Kong, Macau, Taiwan, and Israel.
Comments